Child's Nervous System

, Volume 28, Issue 1, pp 111–115 | Cite as

Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center

  • Canan Akyüz
  • Hacı Ahmet DemirEmail author
  • Ali Varan
  • Bilgehan Yalçın
  • Tezer Kutluk
  • Münevver Büyükpamukçu
Original Paper



Temozolomide is an active drug against gliomas in adults. It also has some promising effects in pediatric patients with brain tumors. We have conducted a retrospective study to investigate the effectiveness of temozolomide in patients with relapsed brain tumors.

Patients and methods

The files of 14 children treated at our hospital between 2005 and 2010 with the diagnoses of relapsed brain tumors were reviewed for pathological characteristics, treatment results, and outcomes.


The median age at relapse was 8 years (range, 1.08–23; F/M, 5/9). Diagnoses included medulloblastoma (n = 5), atypical teratoid rhabdoid tumor (n = 2), ependymoma (n = 2), glioneuronal tumor (n = 1), malignant neoplasm (n = 1), pontine glioma (n = 1), astrocytoma grade III (n = 1), and glioblastoma multiforme (n = 1). All patients except the one with pontine glioma had undergone surgical resection, and all had prior adjuvant chemotherapy. Twelve out of 14 patients had received radiotherapy. The median number of temozolomide courses was 5.0 (range, 1–24). Objective response rate in our patients was 35.7% (three complete responses, one partial response, and one minor response). Stable disease achieved in 14.3% of patients and 50% had progressive disease. Median survival time was 8 months (range, 1–55). At the end of the study, three patients were alive. Hematological toxicity was seen in 30.8% of all courses.


Relapsed brain tumors in childhood have an unfavorable prognosis. These data suggest that temozolomide might be an active agent against recurrent medulloblastoma. Although overall objective response rate was low, further multicentric studies with temozolomide may be warranted in children with recurrent brain tumors.


Temozolomide Relapse Brain tumor Medulloblastoma Children Radiotherapy Chemotherapy Surgery 


  1. 1.
    Sterba J, Pavelka Z, Slampa P (2002) Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49:117–120PubMedGoogle Scholar
  2. 2.
    Loh KC, Willert J, Meltzer H (2005) Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Pediatr Hematol Oncol 27:254–258PubMedCrossRefGoogle Scholar
  3. 3.
    Wang CH, Hsu TR, Wong TT, Chang KP (2009) Efficacy of temozolomide for recurrent embryonal brain tumors in children. Childs Nerv Syst 25:535–541PubMedCrossRefGoogle Scholar
  4. 4.
    Ruggiero A, Cefalo G, Garre ML et al (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77:89–94PubMedCrossRefGoogle Scholar
  5. 5.
    Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691PubMedCrossRefGoogle Scholar
  6. 6.
    Nicholson HS, Kretschmar CS, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110:1542–1550PubMedCrossRefGoogle Scholar
  7. 7.
    Akyüz C, Varan A, Küpeli S et al (2008) Medulloblastoma in children: a 32-year experience from a single institution. J Neurooncol 90:99–103PubMedCrossRefGoogle Scholar
  8. 8.
    Ruggiero A, Rizzo D, Attina G et al (2010) Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma. Eur J Cancer 46:2943–9PubMedCrossRefGoogle Scholar
  9. 9.
    Varan A, Akyüz C, Akalan N et al (2007) Astrocytic tumors in children: treatment results from a single institution. Childs Nerv Syst 23:315–319PubMedCrossRefGoogle Scholar
  10. 10.
    Barone G, Maurizi P, Tamburrini G, Riccardi R (2006) Role of temozolomide in pediatric brain tumors. Childs Nerv Syst 22:652–661PubMedCrossRefGoogle Scholar
  11. 11.
    Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585–2597PubMedGoogle Scholar
  12. 12.
    Khaw SL, Coleman LT, Downie PA (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49:808–811PubMedCrossRefGoogle Scholar
  13. 13.
    Verschuur AC, Grill J, Lelouch-Tubiana A, Couanet D, Kalifa C, Vassal G (2004) Temozolomide in paediatric high-grade glioma: a key for combination therapy? Br J Cancer 91:425–429PubMedCrossRefGoogle Scholar
  14. 14.
    De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A (2006) Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 47:30–36PubMedCrossRefGoogle Scholar
  15. 15.
    Gururangan S, Fisher MJ, Allen JC et al (2007) Temozolomide in children with progressive low-grade glioma. Neuro Oncol 9:161–168PubMedCrossRefGoogle Scholar
  16. 16.
    Estlin EJ, Lashford L, Ablett S et al (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78:652–661PubMedCrossRefGoogle Scholar
  17. 17.
    Nicholson HS, Krailo M, Ames MM et al (1998) Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol 16:3037–3043PubMedGoogle Scholar
  18. 18.
    Korones DN, Smith A, Foreman N, Bouffet E (2006) Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-ınduced malignant gliomas. Pediatr Blood Cancer 47:37–41PubMedCrossRefGoogle Scholar
  19. 19.
    Rubie H, Geoerger B, Frappaz D et al (2010) Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur J Cancer 46:2763–70PubMedCrossRefGoogle Scholar
  20. 20.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  21. 21.
    Broniscer A, Iacono L, Chintagumpala M et al (2005) Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. Cancer 103:133–9PubMedCrossRefGoogle Scholar
  22. 22.
    Athale UH, Duckworth J, Odame I, Barr R (2009) Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol 31:651–63PubMedCrossRefGoogle Scholar
  23. 23.
    Baruchel S, Diezi M, Hargrave D et al (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent pediatric brain tumors. Eur J Cancer 42:2335–2342PubMedCrossRefGoogle Scholar
  24. 24.
    Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  25. 25.
    Mascarin M, Dall'Oglio S, Palazzi M, Sartor G, Marradi PL, Romano M, Maluta S (2010) A case of relapsed medulloblastoma treated with intensity-modulated radiotherapy and temozolomide. Tumori 96:327–331PubMedGoogle Scholar
  26. 26.
    Sirachainan N, Pakakasama S, Visudithbhan A et al (2008) Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol 10:577–582PubMedCrossRefGoogle Scholar
  27. 27.
    Ridola V, Barone G, Lazzareschi I, Ruggiero A, Rizzo D, Riccardi R (2011) Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. J Neurooncol 103:147–153PubMedCrossRefGoogle Scholar
  28. 28.
    Morris EB, Kasow K, Reiss U, Ellison D, Broniscer A (2010) Bone marrow transplantation for severe aplastic anemia secondary to temozolomide. J Neurooncol 91:237–239CrossRefGoogle Scholar
  29. 29.
    Dufour C, Da Costa L, Auger N, Jullien M, Bhangoo R, Grill J (2008) Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. J Pediatr Hematol Oncol 30:857–859PubMedCrossRefGoogle Scholar
  30. 30.
    Momota H, Nariata Y, Miyakita Y, Hosono A, Makimoto A, Shibui S (2010) Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer 55:577–579PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Canan Akyüz
    • 1
  • Hacı Ahmet Demir
    • 1
    Email author
  • Ali Varan
    • 1
  • Bilgehan Yalçın
    • 1
  • Tezer Kutluk
    • 1
  • Münevver Büyükpamukçu
    • 1
  1. 1.Institute of Oncology, Department of Pediatric OncologyHacettepe UniversityAnkaraTurkey

Personalised recommendations